The growing problem of benign connective tissue tumours
Mené sur 25 patients atteints d'une synovite villonodulaire pigmentée de stade localement avancé, cet essai de phase I évalue la dose maximale tolérée et la toxicité de l'emactuzumab, un anticorps monoclonal inhibant l'activation du récepteur CSF1
Medical oncology has traditionally focused on malignant tumours of the connective tissue, which represent a major burden of disease in most communities. Although few public registries mandate reporting, evidence suggests that benign tumours of the soft tissue could be 100 times more common than are malignant tumours. Moreover, the prevalence of benign tumours could be much higher than the incidence, because they are less lethal. For the most part, benign connective tissue tumours are managed surgically, usually curatively.
The Lancet Oncology 2015